Mawer Investment Management Ltd. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 831,553 shares of the biopharmaceutical company’s stock after purchasing an additional 3,380 shares during the quarter. Mawer Investment Management Ltd.’s holdings in Gilead Sciences were worth $52,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. S&CO Inc. increased its holdings in Gilead Sciences by 5.5% in the 4th quarter. S&CO Inc. now owns 6,325 shares of the biopharmaceutical company’s stock worth $396,000 after acquiring an additional 330 shares during the last quarter. Addenda Capital Inc. increased its holdings in Gilead Sciences by 2.3% in the 4th quarter. Addenda Capital Inc. now owns 59,731 shares of the biopharmaceutical company’s stock worth $3,735,000 after acquiring an additional 1,362 shares during the last quarter. IMA Wealth Inc. increased its holdings in Gilead Sciences by 31.6% in the 4th quarter. IMA Wealth Inc. now owns 7,121 shares of the biopharmaceutical company’s stock worth $445,000 after acquiring an additional 1,710 shares during the last quarter. Clear Perspective Advisors LLC increased its holdings in Gilead Sciences by 3.6% in the 4th quarter. Clear Perspective Advisors LLC now owns 8,680 shares of the biopharmaceutical company’s stock worth $543,000 after acquiring an additional 300 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Gilead Sciences by 199,789.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock worth $2,420,587,000 after acquiring an additional 31,335,030 shares during the last quarter. Institutional investors own 78.23% of the company’s stock.

A number of research analysts have weighed in on GILD shares. ValuEngine lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Oppenheimer raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a report on Thursday, January 3rd. Wells Fargo & Co reduced their target price on Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a report on Tuesday, February 5th. CIBC raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a report on Thursday, January 3rd. Finally, BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, February 7th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $82.29.

Shares of GILD opened at $65.63 on Friday. The stock has a market cap of $82.69 billion, a PE ratio of 10.67, a price-to-earnings-growth ratio of 4.08 and a beta of 1.16. The company has a quick ratio of 3.29, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $80.90.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business’s revenue was down 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.78 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date of this dividend is Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio (DPR) is 37.07%.

In other news, Director Gayle E. Wilson sold 19,068 shares of Gilead Sciences stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the sale, the director now owns 143,567 shares in the company, valued at approximately $9,630,474.36. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.16% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Marea Informative and is the property of of Marea Informative. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.mareainformativa.com/news/2019/03/17/gilead-sciences-inc-gild-stake-raised-by-mawer-investment-management-ltd.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Further Reading: Do Tariffs Work?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.